10-Q: Regional Health Properties Q3: Merger Boosts Revenue, OTCQB Challenges

Regional Health Properties reports a significant revenue increase and net income for Q3 2025, driven by the SunLink merger, despite facing liquidity challenges and delisting to OTCQB.

Summary

• Net income for the three months ended September 30, 2025, was $3.382 million, a substantial improvement from a net loss of $(0.982) million in the same period of 2024.
• Total revenues for Q3 2025 increased by 258.3% to $15.138 million, compared to $4.225 million in Q3 2024, primarily due to the SunLink merger and the addition of pharmacy revenues.
• For the nine months ended September 30, 2025, net income was $0.671 million, reversing a net loss of $(2.650) million in the prior year period.
• Total revenues for the nine months ended September 30, 2025, grew by 155.5% to $32.385 million, up from $12.675 million in the same period of 2024.
• The company recognized a gain on bargain purchase of $5.311 million resulting from the merger with SunLink Health Systems, Inc. on August 14, 2025.
• Patient care revenues for the Healthcare Services segment increased by 280.3% to $9.831 million in Q3 2025, due to the company taking over operations of four previously leased facilities.
• Pharmacy revenues, a new segment post-merger, contributed $4.004 million in Q3 2025.
• The company's common stock and Series A Preferred Stock were delisted from NYSE American on June 11, 2025, and now trade on the OTCQB under symbols RHEP and RHEPA, respectively.
• Total assets increased to $72.150 million as of September 30, 2025, from $60.465 million at December 31, 2024.
• Total liabilities increased to $68.997 million as of September 30, 2025, from $63.384 million at December 31, 2024.
• Stockholders' deficit improved to $(1.538) million as of September 30, 2025, from $(2.919) million at December 31, 2024.
• Net cash used in operating activities was $1.0 million for the nine months ended September 30, 2025, primarily due to working capital fluctuations.
• The company completed the sale of its Coosa Valley Health and Rehab facility on November 6, 2025, for $10.6 million, expecting a gain of approximately $3.7 million in Q4 2025.

Sentiment

Score: 6

Explanation: The company demonstrates significant financial improvement with a return to net income and substantial revenue growth, largely due to the strategic SunLink merger and a bargain purchase gain. The successful asset sale further bolsters liquidity. However, the delisting to OTCQB poses material challenges to market access and capital raising. The new pharmacy segment introduces several specific operational and regulatory risks. While management is actively addressing liquidity and operational efficiency, the combination of strong merger-driven performance and significant market/operational headwinds results in a moderately positive, but cautious, outlook.

Positives

• Achieved net income of $3.382 million in Q3 2025, a significant turnaround from a net loss of $(0.982) million in Q3 2024.
• Reported substantial revenue growth, with total revenues increasing by 258.3% in Q3 2025 and 155.5% for the nine months ended September 30, 2025, largely driven by the SunLink merger.
• Recognized a significant gain on bargain purchase of $5.311 million from the SunLink merger, indicating the acquisition was made at a favorable price.
• Successfully completed the sale of the Coosa Valley Health and Rehab facility for $10.6 million post-period, expecting a $3.7 million gain and providing additional liquidity.
• Improved stockholders' deficit from $(2.919) million at December 31, 2024, to $(1.538) million at September 30, 2025.
• Maintained compliance with all financial and administrative covenants under outstanding credit related instruments as of September 30, 2025.
• Management concludes it is probable that the company will be able to meet its obligations arising within one year of the filing date.

Negatives

• Delisted from NYSE American to the OTCQB market, which presents challenges including reduced liquidity, wider bid-ask spreads, limited analyst coverage, and increased regulatory burdens for broker-dealers.
• Net cash used in operating activities was $1.0 million for the nine months ended September 30, 2025, primarily due to working capital fluctuations.
• General and administrative expenses increased significantly by 203.3% in Q3 2025 and 105.0% for the nine months ended September 30, 2025, due to increased facility operations and merger-related costs.
• Total liabilities increased to $68.997 million at September 30, 2025, from $63.384 million at December 31, 2024.
• Adjusted EBITDA from operations decreased to $413 thousand in Q3 2025 from $998 thousand in Q3 2024, and to $982 thousand for 9M 2025 from $2,564 thousand for 9M 2024, indicating a decline in core operating performance when excluding certain items.

Risks

• Trading on the OTC Markets presents challenges including reduced liquidity, wider bid-ask spreads, and limited analyst coverage, which could depress trading prices and negatively impact the company's ability to raise capital.
• Broker-dealers face greater regulatory burdens for OTCQB trading, which may further discourage trading activity in the company's securities.
• The limitations of OTCQB trading may impair the company's ability to invest in future growth or refinance upcoming debt maturities.
• Pharmacy operations may be adversely affected by changes in government reimbursement regulations and payment levels (Medicare, Medicaid, Part B CAP program).
• The Durable Medical Equipment (DME) service line of the Pharmacy business may be adversely affected by further changes in government reimbursement regulations and competitive bidding procedures.
• Shortages of key products could adversely affect the Pharmacy business, as many products are susceptible to supply shortages and manufacturers may lack adequate capacity.
• The Pharmacy business is highly dependent on one key supplier, historically accounting for approximately 75% of its cost of goods sold; the loss of this supplier could have a material adverse effect.
• The Pharmacy business has few long-term contracts with its suppliers, and arrangements can be canceled on minimal notice.
• Loss of one or more larger institutional pharmacy customers could significantly reduce revenues and profitability of the Pharmacy business.
• Failure of the Pharmacy business to maintain eligibility as a Medicare and Medicaid supplier or to expand relationships with private payors could materially adversely affect its competitive position.
• Changes in average wholesale prices (AWP) could reduce pricing and margins for the Pharmacy business, especially with government payors and potential new pricing information like average sales price.
• The Pharmacy business faces numerous competitors, many of whom are significantly larger and have greater financial resources.
• Industry trends in managed care contracting and consolidation could adversely affect the Pharmacy business if it is unable to obtain managed care contracts or pharmacy products at reasonable costs.
• Slower than expected growth in the Pharmacy business market, or delays in government reimbursement for new products, could adversely affect revenues.
• A decrease in the introduction of new brand name and generic prescription drugs could adversely affect the profitability of the Pharmacy business.
• The company is a party to various legal actions and administrative proceedings, including claims related to patient injury or death, professional and general negligence, and employment matters, with unpredictable outcomes.
• The company and its tenants are continuously subject to state and federal regulatory scrutiny, including investigations and audits, which could lead to significant regulatory action.
• The self-insurance reserve for professional and general liability claims may not be sufficient to cover actual settlement amounts or legal costs.
• The company has an indemnity agreement with Aspire Sublessees, capped at $8.0 million, for liabilities arising from a former operator.
• The company assumed all prior debts, liabilities, obligations, and duties of SunLink by operation of law following the merger.

Future Outlook

Management intends to grow operations, streamline costs, and increase liquidity by refinancing or repaying debt, expanding borrowing arrangements, increasing lease revenue through acquisitions and property reinvestments, modifying lease terms, replacing non-performing tenants, and reducing general and administrative expenses through SunLink business integration. The company anticipates collecting past due rent and expects to access liquidity from cash on hand, operating cash flows, investing activities, and debt refinancing to meet its obligations over the next twelve months.

Management Comments

• The Company continues to take strategic steps to strengthen its liquidity position and support long-term growth.
• Management is actively working to accelerate the collection of aged patient receivables.
• Management anticipates access to several sources of liquidity, including cash on hand, cash flows from operations, cash flows from investing and debt refinancing during the twelve months following the date of this filing.
• The Company concludes that it is probable that the Company will be able to meet its obligations arising within one year of the date of issuance of these consolidated financial statements within the parameters set forth in the accounting guidance.

Industry Context

Regional Health Properties operates in the highly regulated long-term care, senior housing, and now, pharmacy services industries. The acquisition of SunLink and its pharmacy segment represents a strategic diversification within the healthcare sector, aiming for business synergies and a broader service offering. However, the delisting from NYSE American to OTCQB significantly impacts the company's market visibility and access to capital, contrasting with typical exchange-listed companies. The company faces common industry challenges such as changes in government reimbursement policies (Medicare/Medicaid) and competitive bidding for durable medical equipment, which are prevalent risks in the healthcare services landscape.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in various legal actions and administrative proceedings arising in the ordinary course of business, including claims that services provided during SNF operations resulted in injury or death to patients.
• One specific professional and general liability action alleges negligence due to failure to provide adequate and competent staff, resulting in injuries, pain, suffering, mental anguish, and malnutrition, seeking unspecified actual, compensatory, and punitive damages. This action is covered by insurance, except for punitive damages.
• The company and its tenants are continuously subject to state and federal regulatory scrutiny, supervision, and control, including inquiries, investigations, examinations, audits, site visits, and surveys.
• There is an anticipated increase in governmental investigations of long-term care providers, particularly concerning Medicare and Medicaid false claims, which could lead to enforcement actions.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Common stockholders face reduced liquidity and market visibility due to delisting to OTCQB. Series B Preferred stockholders received a common stock dividend and some shares were repurchased. SunLink shareholders received common stock and new Series D Preferred Stock, which carries specific governance rights and dividend potential.
• Employees: The SunLink merger likely led to integration efforts and potential changes for employees of both entities. A new officer was hired with an inducement grant of restricted stock.
• Customers (Patients/Clients): The expansion into pharmacy services offers new product and service lines. The company continues to operate healthcare facilities, providing patient care.
• Creditors: The company remains in compliance with all debt covenants. Anticipated debt repayments and refinancing efforts are underway to manage existing indebtedness.
• Suppliers: The Pharmacy business has a high dependence on one key supplier (75% of COGS), which poses a risk to supply chain stability and profitability if that relationship changes.

Next Steps

• Accelerate the collection of aged patient receivables.
• Negotiate various methods to collect remaining unpaid rent.
• Refinance or repay existing debt to reduce interest costs and mandatory principal repayments, potentially through expanded borrowing arrangements.
• Increase future lease revenue through acquisitions and reinvestments in existing properties.
• Modify the terms of existing leases with tenants.
• Replace certain tenants who default on their lease payment terms.
• Reduce other and general and administrative expenses.
• Integrate the SunLink businesses to reduce duplicative expenses.
• Achieve a National Market Listing for common stock by specific milestone dates (First Milestone Date: 6th month post-merger, Second: 12th month, Third: 18th month, Fourth: 24th month) to avoid automatic reduction in the Series D Preferred Stock conversion ratio.

Key Dates

Recommendation

The company's Q3 2025 results show a significant turnaround to net income and substantial revenue growth, primarily driven by the strategic SunLink merger and a favorable bargain purchase gain. The recent sale of the Coosa facility further strengthens liquidity. However, the delisting from NYSE American to OTCQB presents material challenges to market liquidity, capital raising capabilities, and investor visibility. The newly acquired pharmacy segment, while diversifying revenue, introduces specific risks related to government reimbursement, supplier dependence, and intense competition. While management is actively pursuing initiatives to improve liquidity and operational efficiency, the combination of positive financial momentum from the merger and the significant headwinds from the delisting and new business risks suggests a 'Hold' recommendation. Investors should monitor the successful integration of the SunLink business, the company's ability to navigate OTCQB trading challenges, and progress on debt refinancing and liquidity initiatives.

Keywords

Healthcare Real Estate, Skilled Nursing Facilities, Senior Housing, Pharmacy Services, Merger, Acquisition, SunLink Health Systems, SEC Filing, 10-Q, Financial Results, OTC Markets, Delisting, Liquidity, Debt Covenants, Patient Care Revenue, Bargain Purchase, Preferred Stock, Corporate Governance, Risk Factors